Print this article

CORDEN PHARMA – Oligonucleotide development trends: Growing Interest in oncology therapies

Keywords:

e-version image

Click HERE to download the PDF version





Matthieu Giraud PhD

Director, Global Peptides, Oligonucleotides, Lipids & Carbohydrates Platforms
CordenPharma International

Advances in drug delivery, new technology, and a deeper understanding of oligonucleotides have led to escalating interest in developing these promising compounds. Research on these chemically synthesized compounds began about 50 years ago to address a wide range of conditions considered “undruggable” with small-molecule therapeutics. While development, delivery and regulatory challenges along with trial failures discouraged many developers, there has been a renewal of interest in oligonucleotides since early 2014, according to the numbers of NCEs entering clinical Phase I.

CLINICAL TRIALS: DELAYED PROGRESS

Today, about 170 ...


 

Teknoscienze publisher & event organiser
viale Brianza 22, 20127
Milano – Italy
info@teknoscienze.com
Tel +39 02 26809375

 

 

Subscribe now